PTN News and Press, Palatin Technologies Inc.

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...

2024-06-12 10:27:30 ET More on Palatin Tech Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript Palatin Tech GAAP EPS of -$0.53 misses by $0.03 Palatin Tech Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on Palatin Tech His...

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...

2024-05-15 13:54:09 ET Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Conference Call May 15, 2024, 11:00 ET Company Participants Carl Spana - President, CEO & Director Stephen Wills - CFO, COO, EVP, Treasurer & Secretary Conference Call Participants...

2024-05-15 07:36:15 ET More on Palatin Tech Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide Seeking Alpha’s Quant Rating on Palatin Tech Read the full article on Seeking Alpha For further details see: Palatin Tec...

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Sympt...

2024-05-14 13:22:24 ET More on Palatin Tech Palatin Technologies, Inc. 2024 Q1 - Results - Earnings Call Presentation Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide...

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...

2024-05-02 15:10:06 ET More on Eli Lilly, Palatin Tech, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise GLP-1 drug pri...